CSF3 and cervical cancer: Regarding the usage of G-CSF during concurrent chemoradiotherapy (cisplatin 40 mg/m2 on days 1, 8, 15, 22, 29, and 36) in patients with stage IIB cervical cancer, “use of G-CSFs is suggested only for high-risk patients” was the most frequent response (30.7%, n = 35) (Table 6).